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This study analyzes the suppression of sweat gland
activity by botulinum toxin type B. We injected botuli-
num toxin type B (between 2 and 1000 mouse units sub-
cutaneously) in the lateral side of both lower legs in 15
healthy volunteers. Sweat tests were carried out before
botulinum toxin type B injections, and at 3 wk, 3 mo,
and 6 mo.We studied focal anhidrosis by iodine^starch
staining and by capacitance hygrometry after carbachol
iontophoresis, according to the quantitative sudomotor
axon re£ex test (QSART). Iodine starch staining indi-
cated that a threshold dose of 8 mouse units botulinum
toxin type B leads to anhidrotic skin spots (44 cm2)
after 3 wk. Duration of anhidrosis was prolonged for
3 mo when 15 mouse units and for 6 mo when 125 mouse
units botulinum toxin type B were injected. The size of
the anhidrotic area decreased with time (po0.001), indi-
cating partial recovery at the edges. After 3 wk, the
QSART score had signi¢cantly decreased to 18% of
baseline and had decreased to zero in most subjects
with doses of 62.5 mouse units or more. After 3 mo,
the QSART had returned to 91% of baseline in all but
one subject and, after 6 mo, recovery of sudomotor
function was complete. Analysis by iodine^starch stain-
ing and QSART indicated that botulinum toxin type B
suppresses sudomotor function e¡ectively, in a concen-
tration-dependent manner. Key words: autonomic nervous
system/botulinum toxin B/iodine starch staining/sweating. J
Invest Dermatol 121:1312 ^1316, 2003
T
he family of botulinum toxins includes seven clostri-
dial neurotoxins (types A^G), which block neuro-
muscular transmission. Botulinum toxin type A
(BoNT/A) was used e¡ectively to treat a range of
movement disorders ( Jankovic and Schwartz, 1993).
BoNT/A also blocks autonomic nerve function and is e¡ective
in focal hyperhidrosis and hypersalivation (Heckmann et al,
2001). Recently, Botulinum toxin type B (BoNT/B) has been ap-
proved for the treatment of cervical dystonias (Lew et al, 2000).
Both BoNT/A and BoNT/B are di-chain proteins of heavy and
light chains that act preferentially in cholinergic nerves. Heavy
chains determine neuron-speci¢c binding. Light chains act intra-
cellularly to inactivate the fusion protein complex, which is ne-
cessary for the exocytosis of acetylcholine. Botulinum toxins
therefore block neuromuscular transmission, causing muscle
weakness and atrophy. For BoNT/A, intracellular degradation is
slow and it therefore takes 3 to 4 mo before muscle weakness is
reversed (Zimmermann, 1996). For other toxin types, intracellular
degradation is faster or they have di¡erent intracellular targets
than BoNT/A. Therefore, the e¡ects of BoNT/A and BoNT/B in
humans di¡er. Clinical and in vivo studies have shown that
BoNT/A is 20 to 50 times more e¡ective in blocking neuromus-
cular transmission than BoNT/B (Sloop et al, 1997). For the treat-
ment of spasmodic torticollis, BoNT/A is used at 100 or 500
(depending on the preparation) lethal mouse doses (mouse units,
MU), whereas BoNT/B is required at 5000 to 10,000 MU. Treating
patients with spasmodic torticollis with BoNT/B, however, fre-
quently causes autonomic side-e¡ects, such as hyposalivation,
accommodation paresis, or reduction of respiratory heart rate
variation. These autonomic side-e¡ects may point to a potential
value of BoNT/B for the treatment of hyperhidrosis.
Recently, we presented a study quantifying the inhibitory
e¡ects of BoNT/A on sudomotor function in humans (Braune
et al, 2001). We found a concentration-dependent reduction in
sweat gland activity, with a minimal dose of 10 MU BoNT/A
(Dysport, Ipsen Pharma, Maidenhead, UK) required to induce
reproducibly focal anhidrosis after subcutaneous injection in
healthy subjects. With doses higher than 50 MU anhidrosis was
maintained for 6 mo.
No quantitative data are available for the inhibitory e¡ects of
BoNT/B on sudomotor nerves. We sought to obtain data for
comparison of BoNT/A and BoNT/B. Therefore we employed
an identical protocol as described in a previous study (Braune
et al, 2001).We thereby intended to analyze the role of BoNT/B
in future treatment strategies for focal hyperhidrosis.
MATERIALS ANDMETHODS
We examined sudomotor function in 15 healthy volunteers (nine men, six
women) before and at 3 wk, 3 mo, and 6 mo after subcutaneous injections
of BoNT/B. All participants were injected on both legs (30 legs) with dif-
ferent doses. We used a commercially available preparation of BoNT/B
(NeuroBloc, Elan Pharmaceuticals, Dublin, Ireland) with an original con-
centration of 5000 U per mL. The toxin doses ranging from 2 to 1000 MU
(Table I) were diluted in 1mL of isotonic saline to yield constant volumes.
BoNT/B was injected subcutaneously, using a 27 G needle, at the lateral
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aspects of calves midway between the ¢bular head and the lateral malleo-
lus. In accordance with the ring-shaped sweat capsule (2.5 cm diameter) of
the quantitative sudomotor axon re£ex test (QSART) device (below), we
used a ¢xed injection scheme with four injections (square, distance 2 cm).
We determined the area of focal anhidrosis and measured sudomotor func-
tion. The local ethics committee of the University of Erlangen approved
the study and all participants gave written informed consent.
Determining the area of focal anhidrosis The patients were accli-
matized in a temperature-controlled and humidity controlled labora-
tory. Sweating was induced by infra-red irradiation and hot tea (Birklein
and Erbguth, 2000). To identify the area of anhidrotic skin after BoNT/B
injection, we used iodine^starch staining (Minor, 1927). Skin that retained
sudomotor function changed from white to dark blue, whereas the
anhidrotic skin remained white. To measure the area of anhidrosis, we
took photographs of both legs with a red^green^blue camera (Cohu 8312,
single charge-coupled device, Cohu, Inc. San Diego, California), and the
pictures were digitized by frame-grabber software (Oculus TCX 2;
Coreco, St Laurent, Quebec, Canada). For calibration, we marked the
corners of an area of 10 cm2 on each photo (Braune et al, 2001).
Measurement of sweating: QSART Transcutaneous iontophoresis (1mA,
5 min) of 1% carbachol directly activated sweat glands via muscarinic
acetylcholine receptors at the stimulation site, and induced sudomotor axon
re£ex sweating via nicotinic acetylcholine receptors on sudomotor axons in
the vicinity (Riedl et al, 1998). In order to assess the axon re£ex sweating, we
placed a sweat chamber (covering 5 cm2 of skin) on those areas of the lower
legs that, at later time points, had been pretreated with BoNT/B. The
respective skin areas were identi¢ed in each subject by landmarks or by
iodine^starch staining, which was performed before. Our sweat chambers
were constructed to consist of two separate compartments: One in the
middle (the stimulation compartment) for the iontophoreses electrode where
‘‘muscarinic sweating’’ occurs, and a circular one around (the measuring
compartment), which covers the nicotinergic sudomotor axon re£ex
skin area (QSART) (Lang et al, 1993). The ability to assess exclusively
the axon re£ex sweating with this method has been demonstrated before
by complete suppression of sweating using local anesthetics (Low et al, 1983).
For the quanti¢cation of sweating, dry nitrogen gas (relative humidity
o5%) was passed through the sweat chambers at a constant £ow (270 mL
per min) causing evaporation. Relative humidity was measured by
capacitance hygrometers (Rotronic AG, Basel, Switzerland), their output
was digitized and stored in a PC for further analysis. QSART was not
performed at 6 mo in those subjects in whom sweating had already
normalized after 3 mo.
First, baseline sweating was recorded for 2 min in each session, then
iontophoreses was started, and sweating was recorded for a further 15 min.
To calculate axon re£ex sweating, the baseline (mean values of the ¢rst
2 min) was subtracted from the original curve, and the area under this
di¡erence curve (AUC) was plotted as an integral function. The volume of
stimulus-evoked sweating was quanti¢ed by computing AUC for 10 min
following iontophoreses (Birklein et al, 1997). As QSART is known to vary
between individuals (e.g., between men and women; Low et al, 1983), results
were expressed as percent change of individual baseline values.
Statistical analysis Signi¢cant di¡erences in results obtained from
di¡erent sessions were identi¢ed byWilcoxon’s matched pairs signed rank
test, corrected for multiple comparisons. Correlations between di¡erent
variables were determined by the Spearman rho correlation coe⁄cient. As
normal distribution could not be assumed in our datasets, nonparametric
statistics were calculated. Accordingly, all values are given as median and
interquartile ranges. p-values less than 0.05 were considered signi¢cant.
Table I. The table shows individual results of QSARTand the corresponding area of anhidrotic skin. Doses of BoNT/B su⁄cient
to suppress QSARTcompletely or to induce focal anhidrosis safely at di¡erent time points are indicated by bold type
QSART % of baseline session Area of anhidrosis in cm2
BoNT/B in MU 3 wk after injection 3 mo after injection 6 mo after injection 3 wk after injection 3 mo after injection 6 mo after injection
1000 0% 10% 149% 120 50 10
1000 0% 0% 121% 52 46 14
1000 22% 55% 172% 53 52 22
500 4% 123% 104% 84 39 0
500 0% 73% 120% 60 36 6
500 0% 50% 170% 36 41 19
250 9% 75% 199% 43 32 15
250 0% 19% 46% 48 27 10
250 0% 37% 158% 42 30 16
125 0% 89% 82% 30 23 8
125 14% 111% 176% 24 18 0
125 0% 42% 92% 32 28 17
63 0% 111% 81% 30 14 0
63 0% 23% 114% 36 12 0
63 57% 193% 125% 27 10 0
31 11% 116% 128% 26 12 0
31 23% 44% Missinga 24 10 0
31 29% 43% 97% 24 12 0
15 68% 124% 141% 18 4 0
15 0% 138% Missinga 23 6 0
15 43% 91% 74% 18 4 0
8 93% 182% ^b 10 4 0
8 102% 126% ^b 5 0 0
8 63% 81% ^b 7 0 0
4 40% 92% ^b 7 0 0
4 152% 162% ^b 0 0 0
4 103% 111% ^b 0 0 0
2 58% 96% ^b 0 0 0
2 132% 119% ^b 0 0 0
2 136% 161% ^b 4 0 0
aSubject refused to participate in QSART a third time.
bQSARTwas not performed as it has already normalized after 3 mo with low doses.
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Statistical analysis was performed using the SPSS software package (SPSS
Inc., Chicago, Illinois).
RESULTS
Iodine^starch staining As all subjects had no sweating
abnormalities, iodine^starch staining was not performed before
BoNT/B injection. If doses of 8 MU BoNT/B or more were
injected, iodine^starch staining 3 wk after BoNT/B injection
revealed an anhidrotic skin spot (24.9 cm2; range 6.7^42.0 cm2)
(Table I). After 3 mo, the area of anhidrotic skin decreased (11.7
cm2; 0^30.2), but anhidrosis was still present if more than 15 MU
BoNT/B had been injected previously. After 6 mo, the area of
anhidrotic skin further decreased (0 cm2; 0^10.0, Friedman
w2¼ 48.1, po0.001). With the exception of two subjects,
however, an anhidrotic skin spot remained if 125 MU or more
BoNT/B had been injected. Di¡erences between 3 wk, 3 mo,
and 6 mo were signi¢cant (Wilcoxon, po0.001 each), suggesting
successful recovery of sweat gland function (Table I, Fig 1).
The area of anhidrotic skin was BoNT/B concentration
dependent at 3 wk (rho¼ þ 0.97, po0.001), 3 mo (rho¼ þ 0.98,
po0.001), and 6 mo after injection (rho¼ þ 0.75; po0.001)
(Fig 2).
QSART This was performed in all subjects in a session before
BoNT/B injection to provide baseline values. As there is no
di¡erence between right and left legs in healthy subjects (Braune
et al, 2001; Birklein et al, 2002), we pooled measurements for both
legs (AUC of 534 arbitrary units; range 379^744). After 3 wk,
QSART was reduced to 18% of baseline (range 0^64) and even
absent in 10 of 15 subjects with BoNT/B doses of 62.5 MU or
more (Table I). After 3 mo, QSART had almost returned to
baseline (91% of baseline; range 44^123) in all but one subject.
After 6 mo, QSART scores had returned to baseline or even
exceeded baseline (123%; range 93^156, Friedman w2¼ 27.4,
po0.001). The recovery in sudomotor function observed with
the QSART between 3 wk and 3 mo was signi¢cant (Wilcoxon,
po0.001;Table I).
Similar to iodine^starch staining, suppression of sweating in
the QSART was BoNT/B concentration dependent. This
concentration dependence was shown in a signi¢cant negative
correlation between QSART and BoNT/B doses after 3 wk
(rho¼ ^0.79; po0.001) and after 3 mo (rho¼ ^0.61, po0.001):
QSART scores were higher with lower doses of BoNT/B and
lower with higher doses (Fig 3). After 6 mo, the correlation
became positive, although it was then no longer signi¢cant
(rho¼ þ 0.36, not signi¢cant).
Correlation between QSART and area of anhidrotic
skin Three weeks after BoNT/B injection, there was a
signi¢cant negative correlation between QSART and the
anhidrotic skin area (rho¼ ^0.83; po0.001), which was weaker
but still present after 3 mo (rho¼ ^0.60, po0.001). After 6 mo
there was positive correlation between QSART and anhidrotic
skin area (rho¼ þ 0.57, po0.01).
Dose thresholds and duration of BoNT/B anhidrotic e¡ects
Anhidrosis was maintained for 3 wk after administration of doses
of 8 MU BoNT/B per 4 cm2 skin. Anhidrosis was maintained for 3
mo if 15 MU BoNT/B per 4 cm2 were injected. Accordingly, when
BoNT/B dose and area of anhidrotic skin were plotted, the slope
of the line of regression at lower dose ranges was 0.49 after 3 wk
and 0.21 after 3 mo. In other words, we had to inject 2 MU per cm2
to ensure a reduction in local sweat gland activity, which could be
maintained for 3 mo if 4 or 5 MU per cm2 were used. Anhidrotic
skin could be detected even after 6 mo if 125 MU per 4 cm2 (about
30 MU per cm2) had been injected previously; however, anhidrosis
was then no longer concentration dependent (Fig 2).
Side-e¡ects No subject reported any serious side-e¡ects. Even
the highest doses of BoNT/B (1000 MU) induced neither
permanent nor transient weakness of underlying muscles. No
distant autonomic side-e¡ects, such as dry mouth or eyes, were
reported.
DISCUSSION
This study revealed that BoNT/B blocks sweating after subcuta-
neous application in a concentration-dependent manner. This
anhidrosis was not transient; it could be maintained for 3 mo
with small doses and for 6 mo with larger doses. As very large
doses are usually required to block motor neurons, BoNT/B is
much more e¡ective in blocking sudomotor nerves than motor
neurons in humans.
Di¡erences between BoNT/B and BoNT/A: implications for
therapeutic strategy There are obvious di¡erences between
Figure1. Specimen of iodine starch
staining. Injection of 250 MU BoNT/B
caused an anhidrotic skin of 41.6 cm2 after
3 wk, 29.5 cm2 after 3 mo. and 15.8 cm2
after 6 mo. Accordingly, area of anhidrotic
skin after 62.5 MU BoNT/B was 27 cm2
after 3 wk, 9.5 cm2 after 3 mo, and no
longer present after 6 mo. Note di¡erent
scales in right lower corner of each photo
representing 1 cm.
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BoNT/A and BoNT/B e⁄cacy in inhibiting motor function in
humans (Brin et al, 1999). BoNT/A (Dysport, Ipsen Pharma) is
between 20 and 50 times more potent in treating spasmodic
torticollis in humans than BoNT/B (NeuroBloc, Elan
Pharmaceuticals), as measured in lethal mouse doses. In a
previous investigation, employing the same investigation
protocol as presented here, we have shown that a minimum dose
of 10 MU BoNT/A (Dysport) causes a local anhidrotic skin patch
and 80 MU abolishes sweat gland activity, measured by QSART,
after 3 wk. A minimum dose of 50 MU BoNT/Awas e¡ective to
maintain focal anhidrosis for 6 mo, but QSART recovered in all
subjects, even if 120 MU had been injected (Braune et al, 2001).
This study shows that BoNT/B is comparably e¡ective as
BoNT/A in blocking sudomotor function for 3 mo. Slightly
higher doses of BoNT/B (125 MU) than BoNT/A (50 MU,
Dysport) were needed to maintain anhidrosis for 6 mo,
indicating that recovery of sudomotor function is better with
BoNT/B. This shorter-lasting e¡ect of BoNT/B is in accordance
with previous investigations of motor recovery (Hanna and
Jankovic, 1998). The higher a⁄nity of BoNT/B for the
sudomotor nerve than for the motor neuron has two e¡ects:
autonomic side-e¡ects are observed more frequently with
BoNT/B therapy of muscular hypercontractions than with
BoNT/A because the high doses of BoNT/B required to a¡ect
motor function in£uence the autonomic nervous system and lead
to distant side-e¡ects. On the other hand, however, when BoNT/
B is injected to treat hyperhidrosis in sensitive skin areas such as
palms or soles, muscle weakness is unlikely to be a side-e¡ect.
The molecular reasons why BoNT/B preferentially blocks
autonomic nerves remain unclear. Toxin type-speci¢c binding
of toxin heavy chains to di¡erent cholinergic nerves may play a
part (Brin, 1997), or the intracellular target of BoNT/B,
synaptobrevin, may have di¡erent importance for exocytosis in
motor and sudomotor nerves (Lalli et al, 1999). This study
suggests that in motor nerves synaptobrevin is restored more
e¡ectively than SNAP25, the intracellular target of BoNT/A.
Dose estimation for future therapeutic applications From
this study, one can calculate that BoNT/B at a dose of 5 MU per
cm2 must be injected every 3 mo to maintain anhidrosis. For
example, if axillary hyperhidrosis occurs in an area of 100 cm2,
repeated injections of 500 MU BoNT/B should maintain
anhidrosis permanently.We investigated only healthy subjects, as
in our BoNT/A study (Braune et al, 2001). As sweat glands and
sudomotor nerves do not substantially change their functional
properties in hyperhidrosis, there is no physiologic reason to
doubt that similar results would be obtained in hyperhidrosis
patients. Nevertheless, therapy studies in hyperhidrosis are needed
to establish e¡ective doses of BoNT/B. For dose ¢nding there is a
further source of variability.We diluted all doses of BoNT/B in
saline to yield constant volumes. BoNT/B, however, shows some
Figure 3. There was a concentration-dependent suppression of
QSART by BoNT/B.The ¢gure shows that there was a nonlinear nega-
tive correlation between suppression of QSART (in percent of preinjection
baseline) after 3 wk (r¼ ^ 0.79; po0.001) and 3 mo (r¼0.60; po0.001).
At 3 mo, there was a great variability. No further correlation was found
after 6 mo (data not shown).
Figure 2. The area of anhidrotic skin after 3 wk, 3 mo, and 6 mo
was correlated to the doses BoNT/B (po0.001, each time point). At
3 wk (r¼ 0.97) and 3 mo (r¼ 0.98), regression lines had a steeper increase
with lower (2^65 MU, circles) than with higher doses (125^1000 MU,
squares) of BoNT/B. After 6 mo, anhidrosis was present with higher doses
(125^100 MU, squares) only.Then, however, there was obviously no longer a
signi¢cant dose dependency of anhidrosis.
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unspeci¢c binding to glass or plastic surfaces. That is why BoNT/
B is delivered with albumin. By diluting BoNT/B we also diluted
albumin. In the very low-dose range albumin should be too low
to prevent further some unspeci¢c BoNT/B binding. Therefore,
sudomotor blocking e¡ects of BoNT/B in this study might even
be underestimated, in particular in low doses.
Methods of sudomotor testing Focal suppression of sweating
starts 1 d after subcutaneous injection of BoNT/A and the size of
the anhidrotic skin spot increases to a maximum 1 to 2 wk later
(Krmer et al, 2003). In this study, we chose investigation time
points of 3 wk, 3 mo, and 6 mo because recovery of sweat
function occurs during this time (Braune et al, 2001). We
measured sweat production in two ways: iodine^starch staining
indicates clinically relevant impairment of sweating, and
QSART provides quantitative information on BoNT/B e⁄cacy
(Braune et al, 2001). Results obtained with both methods were
highly correlated and demonstrated a concentration-dependent
reduction of sweating after BoNT/B injection. Iodine^starch
staining is an easy bedside test and is sensitive enough to
visualize even small areas of anhidrosis. QSART requires a more
complex experimental set-up (Lang et al, 1993), and iontophoresis
of carbachol is obviously a more intense stimulus than
physiologic activation of sweat glands. The di¡erence in stimuli
may be the major reason for di¡erent results, particularly with
lower BoNT/B doses. Interestingly, the QSART score was
occasionally above baseline values in the low-dose range. This is
similar to a previous study on BoNT/A (Braune et al, 2001). This
phenomenon may be related to a so-called ‘‘perilesional
hyperhidrosis’’ (Low and Kennedy, 1997) and may also explain
increased QSART responses observed in very early cases of
polyneuropathy (Low et al, 1983).
CONCLUSIONS
In conclusion, our results suggest a promising role of BoNT/B in
future therapies for focal hyperhidrosis. If our results are repli-
cated in patients, BoNT/B could become the therapy of choice,
and replace BoNT/A in hyperhidrosis therapy.
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